Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights

Analysts' ratings for Pacira BioSciences PCRX over the last quarter vary from bullish to bearish, as provided by 6 analysts.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $47.17, along with a high estimate of $57.00 and a low estimate of $38.00. Experiencing a 2.54% decline, the current average is now lower than the previous average price target of $48.40.

Interpreting Analyst Ratings: A Closer Look

A clear picture of Pacira BioSciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pacira BioSciences compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Pacira BioSciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Pacira BioSciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Pacira BioSciences analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Pacira BioSciences: A Closer Look

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Pacira BioSciences: Financial Performance Dissected

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 4.23%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Pacira BioSciences's net margin is impressive, surpassing industry averages. With a net margin of 5.37%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Pacira BioSciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.02%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Pacira BioSciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.57%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.65.

Understanding the Relevance of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.